Publicaciones en colaboración con investigadores/as de Transylvania University of Brașov (32)

2024

  1. Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence–Assisted ARIA Care Pathways (ARIA 2024)

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 12, Núm. 10, pp. 2648-2668.e2

2023

  1. Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 11, pp. 2851-2874

  2. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 5, pp. 1169-1203

2022

  1. COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals—EAACI recommendations

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 77, Núm. 8, pp. 2313-2336

  2. EAACI Biologicals Guidelines—Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12–17 years old

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 77, Núm. 1, pp. 17-38

2021

  1. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy

    Clinical and Translational Allergy, Vol. 11, Núm. 4

  2. Biologicals in atopic disease in pregnancy: An EAACI position paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 71-89

  3. COVID-19 pandemic and allergen immunotherapy—an EAACI survey

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 11, pp. 3504-3516

  4. COVID-19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 3, pp. 648-676

  5. EAACI Biologicals Guidelines—Recommendations for severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 14-44

  6. EAACI Biologicals Guidelines—dupilumab for children and adults with moderate-to-severe atopic dermatitis

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 4, pp. 988-1009

  7. EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 6, pp. 1629-1639

  8. Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 45-58

  9. Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 8, pp. 2337-2353

  10. Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 59-70

  11. Management of anaphylaxis due to COVID-19 vaccines in the elderly

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 10, pp. 2952-2964

  12. Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 6, pp. 1640-1660

2020

  1. Anwendung von biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie

    Allergologie, Vol. 43, Núm. 7, pp. 255-271

  2. Biologicals in allergic diseases and asthma: Toward personalized medicine and precision health: Highlights of the 3rd EAACI Master Class on Biologicals, San Lorenzo de El Escorial, Madrid, 2019

    Allergy: European Journal of Allergy and Clinical Immunology

  3. Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 11, pp. 2764-2774